ArticleInternational journal of general medicine2026
An Injectable AAm-DMAEMA/Alg-Ca
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intervertebral disc degeneration (IVDD) is a major cause of low back pain and imposes a significant burden on individuals and society. Bioactive materials are widely used for tissue repair. Here, we designed a calcium alginate (Alg-Ca Methods: Morphology of AAm-DMAEMA/Alg-Ca Results: AAm treatment significantly enhanced the viability and proliferation of NP cells by almost 50% percent. AAm treatment notably alleviated disc height loss, restored tissue integrity, and increased the DHI value in rat model. MRI images showed that while the endplate signal was decreased in the model group, AAm treatment increased the signal at 4 and 8 weeks post-modeling. AAm mitigated disc height loss, improved MRI signals, preserved nucleus pulposus structure, reduced fibrous tissue formation, and promoted bone formation and chondrogenesis. AAm treatment repressed the levels of TNF-α, IL-1, IL-6, and NLRP3 in NP cells. H Conclusion: AAm treatment facilitates the proliferation of NP cells, represses the inflammatory response, alleviates tissue damage, and enhances bone formation in IVDD. These results indicate that AAm-DMAEMA/Alg-Ca
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.